Skip to main content
GemVax & KAEL Co.,Ltd. logo

GemVax & KAEL Co.,Ltd. — Investor Relations & Filings

Ticker · 082270 ISIN · KR7082270000 KO Manufacturing
Open in API
Filings indexed 650 across all filing types
Latest filing 2024-03-20 Director's Dealing
Country KR South Korea
Listing KO 082270

About GemVax & KAEL Co.,Ltd.

https://gemvax.com/

GemVax & KAEL is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics. Its lead drug candidate is GV1001, a synthetic peptide composed of 16 amino acids, which has demonstrated multiple actions including the modulation of neuroinflammation and reduction of oxidative stress. The company's development pipeline primarily targets neurodegenerative diseases, such as Alzheimer's disease and Progressive Supranuclear Palsy (PSP). Other therapeutic areas under investigation include pancreatic cancer and benign prostatic hyperplasia. GemVax & KAEL is actively advancing its programs through clinical trials to evaluate the efficacy and safety of its novel treatments.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service in South Korea. It details the change in share ownership by a director (Kim Sang Jae) of GemVax & Kael. This type of filing is specifically categorized as 'Director's Dealing' (DIRS) as it reports personal share transactions by company executives.
2024-03-20 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from a Korean company (GemVax) detailing a 'Correction Report' regarding a 'Stock Collateral Provision Agreement' involving the company's largest shareholder. This type of disclosure, which details changes in collateralized shares, debt amounts, and creditor information, falls under the category of capital and financing updates as it relates to the company's financing activities and capital structure. It does not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Major Shareholding Notification' (which is for ownership threshold changes). Therefore, it is classified as a Capital/Financing Update.
2024-03-20 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from a Korean company (GemVax) detailing a 'Correction Report' regarding a 'Stock Collateral Agreement' involving the company's largest shareholder. It provides specific details on collateralized shares, debt amounts, and changes to existing agreements. This type of disclosure regarding financing and capital structure changes falls under the 'Capital/Financing Update' category.
2024-03-15 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for the company GemVax. It outlines the date, location, agenda items (financial statements, director appointments, remuneration limits), and details regarding electronic voting. This document serves as the official notification and proxy-related information for an upcoming shareholder meeting, which falls under the Proxy Solicitation & Information Statement category.
2024-03-14 Korean
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a formal notification filed by GemVax & Kael regarding the scheduling of their Annual General Meeting (AGM) on a 'concentrated date' (a date when many companies hold their AGMs). It explains the reasons for this scheduling conflict and confirms non-participation in a voluntary dispersion program. As this is a regulatory disclosure regarding meeting logistics rather than the meeting materials themselves or a voting result, it falls under the general regulatory filing category.
2024-03-14 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (GemVax) announcing a significant change (over 15%) in revenue or profit structure. This type of disclosure is a standard regulatory requirement in the Korean market (KRX) for listed companies to report material financial changes before the final audit is completed. It provides key financial highlights and reasons for the variance, fitting the definition of an Earnings Release (ER) as it serves as an initial announcement of financial results/performance metrics. FY 2023
2024-03-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.